DAVITA INC's ticker is DVA and the CUSIP is 23918K108. A total of 499 filers reported holding DAVITA INC in Q3 2023. The put-call ratio across all filers is 2.89 and the average weighting 0.1%.
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CREDIT AGRICOLE S A | 507 | $47,927 | 0.00% |
| THRIVENT FINANCIAL FOR LUTHERANS | 5,408 | $517 | 0.00% |
| ST GERMAIN D J CO INC | 150 | $14,180 | 0.00% |
| FIFTH THIRD BANCORP | 3,298 | $311,760 | 0.00% |
| M&T BANK CORP | 3,603 | $340,960 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 129,625 | $12,253,452 | 0.00% |
| PNC FINANCIAL SERVICES GROUP, INC. | 15,088 | $1,426,267 | 0.00% |
| PRICE T ROWE ASSOCIATES INC /MD/ | 82,849 | $7,832 | 0.00% |
| VisionPoint Advisory Group, LLC | 35 | $3,309 | 0.00% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 41,506 | $3,923,562 | 0.00% |
| BOYD WATTERSON ASSET MANAGEMENT LLC/OH | 18 | $1,702 | 0.00% |
| WELLS FARGO & COMPANY/MN | 40,000 | $3,781,200 | 0.00% |
| CWM, LLC | 1,123 | $106 | 0.00% |
| MACKENZIE FINANCIAL CORP | 4,438 | $415,929 | 0.00% |
| HEADINVEST, LLC | 35 | $3,329 | 0.00% |
| TWO SIGMA ADVISERS, LP | 5,900 | $557,727 | 0.00% |
| D. E. Shaw & Co., Inc. | 10,000 | $945,300 | 0.00% |
| KEYBANK NATIONAL ASSOCIATION/OH | 2,670 | $252,397 | 0.00% |
| Desjardins Global Asset Management Inc. | 125 | $11,814 | 0.00% |
| RAYMOND JAMES & ASSOCIATES | 14,617 | $1,381,745 | 0.00% |
About DAVITA INC
DaVita Inc. is a leading provider of kidney care services in the United States. The company operates more than 2,700 dialysis clinics across the country, serving approximately 203,000 patients. DaVita's mission is to improve the quality of life for those living with kidney disease, and the company is committed to providing high-quality, compassionate care to its patients.
DaVita's success can be attributed to its focus on patient-centered care. The company's care teams work closely with patients to develop personalized treatment plans that meet their unique needs. DaVita also invests heavily in technology and innovation to improve patient outcomes and enhance the overall patient experience.
In addition to its core kidney care services, DaVita also operates a number of strategic business units, including DaVita Kidney Care, DaVita Medical Group, and DaVita International. These units allow the company to diversify its revenue streams and expand its reach into new markets.
Despite its success, DaVita faces a number of challenges in the highly competitive healthcare industry. The company must navigate complex regulatory environments, manage rising healthcare costs, and adapt to changing patient needs and preferences.
Overall, DaVita is a strong player in the kidney care market, with a proven track record of delivering high-quality care to its patients. As the healthcare industry continues to evolve, DaVita will need to remain agile and innovative to stay ahead of the curve.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
External links
This page lists DAVITA INC's shareholders in Q3 2023. To view DAVITA INC's shareholder history, click here.